美国黑人和白人退伍军人前列腺癌中的可操作基因组改变。
Actionable Genomic Alterations in Prostate Cancer Among Black and White United States Veterans.
机构信息
Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA.
Department of Radiation Oncology, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA.
出版信息
Oncologist. 2023 Jun 2;28(6):e473-e477. doi: 10.1093/oncolo/oyad042.
Black Veterans have higher a incidence of localized and metastatic prostate cancer compared to White Veterans yet are underrepresented in reports of frequencies of somatic and germline alterations. This retrospective analysis of somatic and putative germline alterations was conducted in a large cohort of Veterans with prostate cancer (N = 835 Black, 1613 White) who underwent next generation sequencing through the VA Precision Oncology Program, which facilitates molecular testing for Veterans with metastatic cancer. No differences were observed in gene alterations for FDA approved targetable therapies (13.5% in Black Veterans vs. 15.5% in White Veterans, P = .21), nor in any potentially actionable alterations (25.5% vs. 28.7%, P =.1). Black Veterans had higher rates of BRAF (5.5% vs. 2.6%, P < .001) alterations, White Veterans TMPRSS2 fusions (27.2% vs. 11.7%, P < .0001). Putative germline alteration rates were higher in White Veterans (12.0% vs. 6.1%, P < .0001). Racial disparities in outcome are unlikely attributable to acquired somatic alterations in actionable pathways.
与白人退伍军人相比，黑人退伍军人的局部和转移性前列腺癌发病率更高，但在体细胞和种系改变频率的报告中代表性不足。这项对体细胞和推测种系改变的回顾性分析是在一个接受 VA 精准肿瘤学计划（VA Precision Oncology Program）下一代测序的大型前列腺癌退伍军人队列中进行的，该计划为患有转移性癌症的退伍军人提供分子检测。在 FDA 批准的靶向治疗的基因改变方面（黑人退伍军人为 13.5%，白人退伍军人为 15.5%，P =.21），以及任何潜在的可操作改变方面（黑人退伍军人为 25.5%，白人退伍军人为 28.7%，P =.1）均未观察到差异。黑人退伍军人 BRAF（5.5% vs. 2.6%，P <.001）改变的发生率更高，而白人退伍军人 TMPRSS2 融合（27.2% vs. 11.7%，P <.0001）。白人退伍军人推测种系改变的发生率更高（12.0% vs. 6.1%，P <.0001）。在可操作途径中，获得性体细胞改变不太可能导致种族间结局的差异。
Zotero 插件